CEO Robert Galarza describes his company as “23andMe for the cannabis industry.”
He emphasizes the importance of product consistency and establishing consistent strain identities, especially in the medical cannabis space. BLOCKStrain’s technology can help LPs achieve product consistency and the company offers value-added services such as providing LPs with genetic data to track plant evolution. By creating a cannabis registry, BLOCKStrain technology helps distinguish legal cannabis from illicit sources. BLOCKStrain generates revenue through its cannabis testing program.